Health Care & Life Sciences » Pharmaceuticals | Gemphire Therapeutics Inc.

Gemphire Therapeutics Inc. | Mutual Funds

Mutual Funds that own Gemphire Therapeutics Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Vanguard Total Stock Market Index Fund
239,413
1.68%
0
0%
07/31/2018
Baron Opportunity Fund
207,819
1.46%
146,864
0.07%
06/30/2018
Baron Global Advantage Fund
130,871
0.92%
53,785
0.21%
06/30/2018
Vanguard Extended Market Index Fund
124,471
0.87%
2,115
0%
07/31/2018
Baron Discovery Fund
118,359
0.83%
-159,121
0.05%
06/30/2018
Bridgeway Ultra Small Company Market Fund
46,000
0.32%
46,000
0.02%
12/31/2017
Fidelity Spartan Extended Market Index Fund
34,369
0.24%
0
0%
07/31/2018
iShares Micro Cap ETF
28,457
0.2%
0
0%
09/06/2018
Fidelity Spartan Total Market Index Fund
13,477
0.09%
0
0%
07/31/2018
Fidelity Nasdaq Composite Index
12,322
0.09%
0
0%
07/31/2018

About Gemphire Therapeutics

View Profile
Address
17199 North Laurel Park Drive
Livonia Michigan 48152
United States
Employees -
Website http://www.gemphire.com
Updated 07/08/2019
Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It engages in the provision of treatment options for cardiometabolic diseases including dyslipidemia and NASH. It offers a small molecule formulated as a tablet product under the Gemcabene brand.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.